Drugs / CD19-CAR T cell
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06106906 | Jun 2024 → Dec 2025 overdue | systemic lupus erythematosus | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03373071 | Dec 2017 → May 2021 | B-cell acute lymphoblastic leukemia | Bambino Gesù Hospital and Research Institute | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06847269 | May 2025 → Mar 2030 expected | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06081478 | Jan 2022 → Dec 2025 overdue | B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma | Beijing Tongren Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04788472 | Mar 2021 → Aug 2024 | B-cell adult acute lymphocytic leukemia | Zhejiang University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 CAR-T cell | “The dosage for CD19-CAR-T cell was 2×10e6/kg and CD22-CAR-T cell was 1×10e6/kg.” NCT06081478 ↗4“primary end point was CMR rate after CD19 CAR T-cell therapy” PMID 40244598 ↗ Jun 2025 |
| Known as | CD19-CART01 | “Autologous CAR T product directed against CD19-expressing tumor cells (CD19-CART01) will be produced and, after a lymphodepletion with conventional chemoterapic agents, the...” NCT03373071 ↗ |
| Modality | Cell therapy | “Autologous CAR T product directed against CD19-expressing tumor cells” NCT03373071 ↗ |
| Route | Intravenous | “the patient will receive CD19-CART01 intravenously” NCT03373071 ↗ |
| Target | CD19 | “Autologous CAR T product directed against CD19-expressing tumor cells” NCT03373071 ↗ |